Lb Pharmaceuticals (LBRX) Other Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, down 46.37% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.1 million, down from $1.3 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $2.5 million in Q4 2024, with the low at $942000.0 in Q3 2025.
• The 3-year median for Other Non-Current Liabilities is $1.2 million (2025), against an average of $1.5 million.
• Peak annual rise in Other Non-Current Liabilities reached 46.37% in 2025, while the deepest fall reached 46.37% in 2025.
• Lb Pharmaceuticals' Other Non-Current Liabilities stood at $2.5 million in 2024, then tumbled by 46.37% to $1.3 million in 2025, then dropped by 14.89% to $1.1 million in 2026.
• Business Quant data shows LBRX's Other Non-Current Liabilities at $1.1 million in Q1 2026, $1.3 million in Q4 2025, and $942000.0 in Q3 2025.